Govt Job: For M.Pharm, M.Sc at NIPER

NIPER Ahmedabad was initiated with three specializations Biotechnology, Natural Products and Pharmaceutics and over the period of time three more specialisations Pharmaceutical Analysis, Medicinal Chemistry and Pharmacology and Toxicology were added in 2010.

Subsequently in 2011, to cater the needs of Medical device industry in India, another feather was added to the cap of NIPER Ahmedabad in the form of specialisation in Medical Devices.

Post : Junior Research Fellow JRF (1 Post)

Applications are invited from eligible candidates for JRF position in the project funded by DST- SERB. The position is temporary in nature.

Project File No. : SRG/2020/000658/CS

Project Title : Merging Vinylic and Allylic C–H Bonds Activation under Single-Component Serial Palladium Catalysis: Development of Topoisomerase I (ToP I) – Histone Deacetylase (HDAC) Dual Inhibitors

Engagement Period : 4-5 months

Salary : As per DST-SERB norms

Qualification
M.Pharm or Equivalent (with specialization in Medicinal Chemistry / Pharmaceutical Chemistry) / M.Sc. or equivalent (with specialization in Medicinal Chemistry / Organic / Pharmaceutical Chemistry) as evidenced from published papers in standard refereed journals.

PG degree with 60% marks for GN/OBC (55% for SC/ST/PH) from UGC recognized University/ Institute.

Age Limit : 28 years on the date of application, with relaxation to SC/ST/OBC candidates as per Government of India norms.

Job Profile : For this project, the candidate should be: a) Proficient in basic organic chemistry, green chemistry, and analytical techniques. b) Should able to work on transition metal catalysis including but not limited to C- H bond activation protocol

Terms and Conditions
• Interested candidates may send their CV in attached format and cover letter via email to Registrar, NIPER-A (registrar@niperahm.res.in) with a copy to PI at Email : Dr. Dinesh Kumar (dineshk@niperahm.res.in) on or before 14th March, 2023.

Please write “Application for DST-SRF” in the subject line of the email.

• Shortlisted candidates would be intimated by e-mail for the interview (Online/Offline).

• Candidates should bring the printouts of the application form with original and self-attested copies of all the supporting documents at the time of the interview.

• No canvassing in any form will be entertained.

• No TA/DA will be paid for attending the interview

Last date: on or before 14th March, 2023

Related Posts

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

NEW DELHI: The Central Drugs Standard Control Organisation (CDSCO), under the Drugs Controller General of India (DCGI), has issued directives to all State and Union Territory (UT) Licensing Authorities requesting…

Fake Medicines Worth Over Rs 5 Crore Seized From Factory In Uttarakhand’s Dehradun

A joint team of food safety and police officials raided a factory in Dehradun allegedly manufacturing fake medicines of leading pharmaceutical companies. Lucknow: A joint team of the Uttar Pradesh Food…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

Fake Medicines Worth Over Rs 5 Crore Seized From Factory In Uttarakhand’s Dehradun

Fake Medicines Worth Over Rs 5 Crore Seized From Factory In Uttarakhand’s Dehradun

A ‘Fatal Flaw’ might be lurking in apparently Healthy Heart- Dr Devi Shetty

A ‘Fatal Flaw’ might be lurking in apparently Healthy Heart- Dr Devi Shetty

CDSCO declares 159 drug samples as NSQs in June

CDSCO declares 159 drug samples as NSQs in June

Donald Trump reveals 200% tariff plan for generic medicines. Will India exports be hit?

Donald Trump reveals 200% tariff plan for generic medicines. Will India exports be hit?

IIT Kanpur scientists’ research reveals how a promising vaccine booster switches on immune cells

IIT Kanpur scientists’ research reveals how a promising vaccine booster switches on immune cells